Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 4Neoplasm Metastasis 2Lymphatic Abnormalities 2Lymphangioma, Cystic 2Lymphangioma 2Vascular Malformations 1Solid Tumor 1Skin Diseases, Vascular 1Ovarian Neoplasms 1Neoplasms 1Meningioma 1Melanoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Arteriovenous Malformations 1

Interventions

Carboplatin 18Paclitaxel 17Bevacizumab 17olaparib 8Specimen Handling 7liposomal doxorubicin 6pembrolizumab 5Taxes 5Biopsy 5cemiplimab 4Magnetic Resonance Spectroscopy 4sarilumab 3niraparib 3mirvetuximab soravtansine 3Topotecan 3Standard of Care 3Letrozole 3Gemcitabine 3Cisplatin 3130-nm albumin-bound paclitaxel 3taxane 2talazoparib 2palbociclib 2abemaciclib 2Temozolomide 2Surgical Procedures, Operative 2Practice Guidelines as Topic 2Poly(ADP-ribose) Polymerase Inhibitors 2Palliative Care 2Immunoglobulin G 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Fallopian Tube Neoplasms × Alpelisib × Clear all
NCT05564377 2026-06-02

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡